Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Patients With Advanced Solid Tumors
Latest Information Update: 21 May 2025
At a glance
- Drugs TGW 101 (Primary)
- Indications Adenocarcinoma; Breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Tagworks Pharmaceuticals
Most Recent Events
- 22 Apr 2025 According to Tagworks Pharmaceuticals media release, Anthony Tolcher is primary investigator in this trial.
- 22 Apr 2025 According to Tagworks Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for a Phase 1 clinical trial evaluating TGW101.
- 22 Apr 2025 Status changed from planning to recruiting.